From the American College of Rheumatology…
Apremilast (Celgene), an investigational oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), led to significant improvement in the signs and symptoms of psoriatic arthritis in patients who failed to respond to recommended drugs, including DMARDs and biologics, in the phase 3 PALACE-1 trial.
Psoriatic arthritis is a very common type of arthritis and unlike what many physicians think, is not the same as rheumatoid arthritis and must be treated differently.
For more information on arthritis treatments and other arthritis problems, go to:
Just go here Contact